tiprankstipranks
Trending News
More News >
Artra Group Corporation (JP:6029)
:6029
Japanese Market

Artra Group Corporation (6029) AI Stock Analysis

Compare
0 Followers

Top Page

JP:6029

Artra Group Corporation

(6029)

Select Model
Select Model
Select Model
Neutral 57 (OpenAI - 5.2)
Rating:57Neutral
Price Target:
¥146.00
▼(-14.12% Downside)
Action:ReiteratedDate:02/18/26
The score is primarily supported by improving financial health (profitability recovery and deleveraging) and a low P/E valuation, but is held back by weak technicals (below major moving averages with negative momentum) and the fundamental risk of multi-year revenue contraction and earnings/cash-flow volatility.
Positive Factors
Margin recovery & gross margin
Sustained improvement in gross and net margins indicates better pricing power or cost control in core printing operations. Higher margins increase resilience to revenue swings, improve cash conversion and provide room to invest in efficiency or product quality over the next several quarters.
Deleveraging and balance sheet repair
Material reduction in leverage strengthens financial flexibility, lowers interest costs and reduces refinancing risk. A healthier capital structure supports investment or cyclical cushions and makes the company better positioned to withstand downturns or fund strategic initiatives.
Improved cash generation
Positive operating and free cash flow that largely covers reported earnings demonstrates real cash conversion and supports deleveraging and operational needs. Consistent FCF provides durable funding for working capital and modest reinvestment without relying on external financing.
Negative Factors
Multi-year revenue contraction
A persistent top-line decline erodes scale benefits in a manufacturing/printing business, reducing capacity utilization and squeezing long-run unit economics. Continued revenue shrinkage limits margin expansion potential and constrains reinvestment or diversification options.
Earnings and cash-flow volatility
Intermittent net losses and uneven cash flows complicate planning and increase execution risk. Volatility can force reactive measures (pricing cuts, asset sales) in weak quarters, undermine stakeholder confidence and risk re-leveraging if profits reverse.
Order-driven demand cyclicality
Dependence on customer orders and volume mix exposes revenue to industrial and end-market cycles. That structural sensitivity can produce lumpy bookings, underutilized capacity and pricing pressure, making stable growth and margin consistency harder to sustain.

Artra Group Corporation (6029) vs. iShares MSCI Japan ETF (EWJ)

Artra Group Corporation Business Overview & Revenue Model

Company DescriptionArtra Group Corporation provides support services for acupuncture and osteopathic hospitals in Japan. The company offers billing services; and HONEY-STYLE, a system, which specializes in word-of-mouth/reservation system for acupuncture and moxibustion hospital. It also operates Atlas Store, an EC site that sells consumables for acupuncture and moxibustion hospital; and a portal site providing information for judo reduction teachers, acupuncturists/kyu teachers, and anma massage shiatsu teachers through its website and e-mail magazine, as well as offers nursing care services. The company was formerly known as artra corporation and changed its name to Artra Group Corporation in 2021. Artra Group Corporation was founded in 2005 and is headquartered in Osaka, Japan.
How the Company Makes MoneyArtra Group Corporation generates revenue mainly by selling printing and printing-related products and services to business customers. Key revenue streams typically include (1) fees from providing printing services (e.g., production/processing work performed to customer specifications) and (2) sales of printed products and packaging-related outputs delivered to customers. Revenue is recognized through customer orders/contracted jobs and is driven by production volume, order mix, pricing, and customer demand. Specific breakdowns by segment, named major customers, and material partnerships are null.

Artra Group Corporation Financial Statement Overview

Summary
Margins and profitability improved in 2025 (net margin ~6.6%, EBITDA margin ~6.3%) alongside healthier gross margin (~34%) and better leverage (debt-to-equity ~0.62x). Offsetting these gains, revenue has contracted for multiple years and results have been volatile (including a 2024 net loss and historically uneven cash flow).
Income Statement
58
Neutral
Profitability has improved meaningfully versus earlier losses (2020–2021) and the company returned to solid profitability in 2025, with net margin at ~6.6% and EBITDA margin ~6.3%. Gross margin has also strengthened versus 2020 and remains healthy (~34% in 2025). Offsetting this, revenue has been shrinking for several years (down ~3.4% in 2025 after declines in 2023–2024), and earnings have been volatile (net loss in 2024). Overall: better margins and recovery, but weak top-line trajectory and inconsistent bottom-line performance.
Balance Sheet
64
Positive
Leverage is trending in the right direction: debt-to-equity improved from elevated levels in 2021–2023 (above 1.0x) to ~0.62x in 2025, reflecting deleveraging and a stronger equity base. Total assets have been relatively stable, suggesting no major balance sheet contraction. The key watch-out is that leverage was high not long ago and profitability volatility (including the 2024 loss) can pressure equity returns in weaker years.
Cash Flow
61
Positive
Cash generation has improved: operating cash flow and free cash flow are positive in 2024–2025, with 2025 free cash flow covering most of reported earnings (free cash flow is ~86% of net income). However, cash flow has been uneven historically (negative operating/free cash flow in 2021–2022), and free cash flow declined in 2024. Overall: currently supportive of earnings, but the multi-year consistency is not yet fully proven.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue4.07B3.93B4.23B4.50B4.67B3.16B
Gross Profit1.35B1.35B1.33B1.46B1.57B876.25M
EBITDA318.30M246.22M146.84M228.12M190.55M-163.55M
Net Income142.57M258.29M-36.74M53.00M2.10M-351.12M
Balance Sheet
Total Assets3.81B4.13B4.11B4.57B4.65B5.60B
Cash, Cash Equivalents and Short-Term Investments1.02B1.13B1.05B1.14B1.23B1.84B
Total Debt1.18B1.05B1.28B1.53B1.91B2.43B
Total Liabilities2.26B2.43B2.68B3.13B3.35B4.16B
Stockholders Equity1.55B1.70B1.44B1.45B1.31B1.44B
Cash Flow
Free Cash Flow0.00246.64M122.36M142.00M-288.93M-264.76M
Operating Cash Flow0.00287.21M200.85M217.00M-132.55M-208.56M
Investing Cash Flow0.0024.68M-31.16M-11.00M-154.17M-563.84M
Financing Cash Flow0.00-233.24M-259.74M-300.00M-314.62M895.50M

Artra Group Corporation Technical Analysis

Technical Analysis Sentiment
Negative
Last Price170.00
Price Trends
50DMA
163.92
Negative
100DMA
166.30
Negative
200DMA
178.30
Negative
Market Momentum
MACD
-6.33
Positive
RSI
38.50
Neutral
STOCH
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6029, the sentiment is Negative. The current price of 170 is above the 20-day moving average (MA) of 150.75, above the 50-day MA of 163.92, and below the 200-day MA of 178.30, indicating a bearish trend. The MACD of -6.33 indicates Positive momentum. The RSI at 38.50 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6029.

Artra Group Corporation Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
81
Outperform
¥2.95B4.692.82%4.82%9.78%
75
Outperform
¥3.00B27.022.56%-3.06%-38.56%
69
Neutral
¥2.12B15.4132.45%58.25%
60
Neutral
¥5.80B16.774.07%6.08%38.00%
57
Neutral
¥1.46B6.76-10.34%259.78%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
¥1.22B14.802.81%-42.50%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:6029
Artra Group Corporation
142.00
15.00
11.81%
JP:2373
Care Twentyone Corporation
431.00
37.83
9.62%
JP:2425
Care Service Co., Ltd.
790.00
-48.50
-5.78%
JP:7362
Terminalcare Support Institute, Inc.
799.00
-55.00
-6.44%
JP:9214
Recovery International Co.,Ltd.
1,500.00
155.00
11.52%
JP:9220
FB CARE SERVICE CO.,LTD.
1,210.00
269.53
28.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 18, 2026